Astrazeneca Plc (AZN) 33.97 $AZN Pharma Stock R
Post# of 273254
Posted On: 09/24/2016 7:00:56 PM
Astrazeneca Plc (AZN) 33.97 $AZN
Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO
Arpita Dutt - Zacks Investment Research - Fri Sep 23, 7:00AM CDT
Allergan (AGN) remained in the limelight this week thanks to its NASH-focused acquisition deals.
AGN: 243.94 (+0.51), ABT: 42.19 (-0.03), JNJ: 118.81 (-0.65), AZN: 33.97 (-0.31), LLY: 81.16 (-0.13), BMY: 56.48 (+0.06), SNY: 38.35 (-0.22)
AstraZeneca Withdraws Cediranib Marketing Application in EU
Zacks Equity Research - Zacks Investment Research - Thu Sep 22, 8:29AM CDT
AstraZeneca (AZN) announced that its decision to withdraw the Marketing Authorisation Application for cediranib in the EU.
TSRO: 108.59 (+0.16), ANIP: 66.64 (-0.17), AZN: 33.97 (-0.31), PCRX: 36.86 (-0.66)
Watch for AstraZeneca to Potentially Rebound After Falling 1.25% Yesterday
Comtex SmarTrend(R) - Wed Sep 21, 1:39PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $33.21 to a high of $33.53. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $33.46 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 33.97 (-0.31)
AstraZeneca Falls 1.25% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Sep 21, 1:37PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $33.21 to a high of $33.53. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $33.46 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 33.97 (-0.31)
AstraZeneca Diabetes Drug Combination Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Mon Sep 19, 9:28AM CDT
AstraZeneca plc (AZN) announced positive results from a phase III combination trial evaluating the combination of its diabetes drugs Bydureon and Farxiga for the treatment of patients with type II diabetes.
JNJ: 118.81 (-0.65), CBM: 46.60 (+0.30), ANIP: 66.64 (-0.17), AZN: 33.97 (-0.31)
Pharma Stock Roundup: Acquisitions & Deals Pick Up Pace, Aerie Up on Positive Data
Arpita Dutt - Zacks Investment Research - Fri Sep 16, 8:04AM CDT
While Bayer (BAYRY) has signed a merger agreement with Monsanto, Allergan will be acquiring Vitae.
AGN: 243.94 (+0.51), PFE: 34.26 (+0.11), AZN: 33.97 (-0.31), AERI: 39.07 (+1.02), TEVA: 51.47 (+0.24), SNY: 38.35 (-0.22)
Phase III Combination Trial of BYDUREON and FARXIGA Shows Significant Blood Sugar Reduction in Patients with Type 2 Diabetes
BusinessWire - Fri Sep 16, 7:30AM CDT
--The first Phase III trial to assess GLP-1RA/SGLT-2i combination therapy
AZN: 33.97 (-0.31)
SmarTrend Watching for Potential Pullback in Shares of AstraZeneca After 1.03% Gain
Comtex SmarTrend(R) - Thu Sep 15, 12:58PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $33.00 to a high of $33.49. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $33.34 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 33.97 (-0.31)
Downgrade Alert for AstraZeneca (AZN)
Comtex SmarTrend(R) - Wed Sep 14, 3:29AM CDT
AstraZeneca (NYSE:AZN) was downgraded from Outperform to Neutral at Exane BNP Paribas today. The stock closed yesterday at $32.74 on volume of 5.7 million shares, above average daily volume of 3.7 million. In the past 52 weeks, shares of AstraZeneca have traded between a low of $26.97 and a high of $70.67 and closed yesterday at $32.74, which is 21% above that low price. Over the past week, the 200-day moving average (MA) has gone down 2.4% while the 50-day MA has declined 0.2%.
AZN: 33.97 (-0.31)
Biotech Stocks Bounce Back in Monday Trading: 3 Picks
Zacks Equity Research - Zacks Investment Research - Tue Sep 13, 8:12AM CDT
Media and political focus on the high prices of drugs have made things difficult for the pharma/biotech sector since the past one year.
ABT: 42.19 (-0.03), BIIB: 312.58 (-2.23), VNDA: 16.81 (+0.19), PFE: 34.26 (+0.11), AMGN: 174.80 (-0.82), AEGR: 2.75 (+0.10), LLY: 81.16 (-0.13), PDLI: 3.43 (+0.08), JNJ: 118.81 (-0.65), GILD: 81.37 (-0.15), AZN: 33.97 (-0.31), MRK: 62.96 (-0.06), SNY: 38.35 (-0.22), NVS: 81.48 (-0.55)
Upgrade Alert for AstraZeneca (AZN)
Comtex SmarTrend(R) - Tue Sep 13, 3:11AM CDT
AstraZeneca (NYSE:AZN) was upgraded from Hold to Buy at Jefferies today. The stock closed yesterday at $33.24 on volume of 3.6 million shares, below average daily volume of 3.7 million. Over the past year, AstraZeneca has traded in a range of $26.97 to $70.67 and closed yesterday at $33.24, 23% above that low. Over the past week, the 200-day moving average (MA) has gone down 2.4% while the 50-day MA has declined 0.2%.
AZN: 33.97 (-0.31)
Global Cancer Diagnostics Market - Development and Commercialization of Biomarkers for Cancer Diagnostics Opens up Growth Opportunities, Research Report by TMR
GlobeNewswire - Thu Sep 08, 5:44AM CDT
According to the research report, the global cancer diagnostic market is expected to be worth US$168.6 bn by 2020, as the market exhibits a CAGR of 7.6% between 2014 and 2020. Imaging has emerged as a significant segment as the government is making ardent efforts to increase awareness about cancer and cancer diagnostics to better the quality of life. Owing to this reason, imaging will be the most popularly used diagnostic method. The segment will progress at a CAGR of 9.7% between 2014 and 2020. Geographically, North America is anticipated to lead the global cancer diagnostics market at a CAGR of 7.3% between 2014 and 2020.
PFE: 34.26 (+0.11), AZN: 33.97 (-0.31), NVS: 81.48 (-0.55)
Astrazeneca (AZN) Presents Benralizumab Phase III Data
Zacks Equity Research - Zacks Investment Research - Tue Sep 06, 8:08AM CDT
AstraZeneca plc, (AZN) recently announced further results from two pivotal phase III trials on its respiratory disease candidate, benralizumab, for the treatment of severe asthma.
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), AZN: 33.97 (-0.31), ANIK: 46.92 (-1.07)
Benralizumab Phase III Trials Show Positive Results in Severe Asthma
BusinessWire - Mon Sep 05, 7:00AM CDT
Results from pivotal Phase III trials presented at the European Respiratory Society (ERS) International Congress demonstrated that adding benralizumab to standard-of-care medicine significantly reduced exacerbations and improved lung function and asthma symptoms in severe asthma patients with an eosinophilic phenotype, as indicated by the presence of eosinophils in their blood.
AZN: 33.97 (-0.31)
Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:33AM CDT
Biogen (BIIB) granted Fast Track designation in the U.S. for aducanumab for the treatment of early stage Alzheimer's disease.
BIIB: 312.58 (-2.23), AZN: 33.97 (-0.31), LLY: 81.16 (-0.13), ANIK: 46.92 (-1.07)
AstraZeneca Asthma Drug Symbicort Positive in Safety Trial
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:21AM CDT
AstraZeneca PLC (AZN) announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone.
BSTC: 45.26 (+1.22), AZN: 33.97 (-0.31), OHRP: 2.81 (+0.03)
AstraZeneca Announces SYMBICORT Demonstrated Comparable Risk of Serious Asthma-Related Events and Lower Risk of Asthma Exacerbations Compared to Budesonide Alone
BusinessWire - Wed Aug 31, 4:00PM CDT
AstraZeneca today announced results from the SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol LABA (long-acting beta2-adrenergic agonist) safety study showing patients with controlled and uncontrolled asthma had a comparable risk of serious asthma-related events and a lower risk of asthma exacerbations when formoterol was combined with budesonide versus budesonide alone.
AZN: 33.97 (-0.31)
SmarTrend Watching for Potential Rebound in Shares of AstraZeneca After 1.51% Loss
Comtex SmarTrend(R) - Wed Aug 31, 1:35PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $32.61 to a high of $32.84. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $32.78 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 33.97 (-0.31)
Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO
Arpita Dutt - Zacks Investment Research - Fri Sep 23, 7:00AM CDT
Allergan (AGN) remained in the limelight this week thanks to its NASH-focused acquisition deals.
AGN: 243.94 (+0.51), ABT: 42.19 (-0.03), JNJ: 118.81 (-0.65), AZN: 33.97 (-0.31), LLY: 81.16 (-0.13), BMY: 56.48 (+0.06), SNY: 38.35 (-0.22)
AstraZeneca Withdraws Cediranib Marketing Application in EU
Zacks Equity Research - Zacks Investment Research - Thu Sep 22, 8:29AM CDT
AstraZeneca (AZN) announced that its decision to withdraw the Marketing Authorisation Application for cediranib in the EU.
TSRO: 108.59 (+0.16), ANIP: 66.64 (-0.17), AZN: 33.97 (-0.31), PCRX: 36.86 (-0.66)
Watch for AstraZeneca to Potentially Rebound After Falling 1.25% Yesterday
Comtex SmarTrend(R) - Wed Sep 21, 1:39PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $33.21 to a high of $33.53. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $33.46 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 33.97 (-0.31)
AstraZeneca Falls 1.25% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Sep 21, 1:37PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $33.21 to a high of $33.53. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $33.46 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 33.97 (-0.31)
AstraZeneca Diabetes Drug Combination Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Mon Sep 19, 9:28AM CDT
AstraZeneca plc (AZN) announced positive results from a phase III combination trial evaluating the combination of its diabetes drugs Bydureon and Farxiga for the treatment of patients with type II diabetes.
JNJ: 118.81 (-0.65), CBM: 46.60 (+0.30), ANIP: 66.64 (-0.17), AZN: 33.97 (-0.31)
Pharma Stock Roundup: Acquisitions & Deals Pick Up Pace, Aerie Up on Positive Data
Arpita Dutt - Zacks Investment Research - Fri Sep 16, 8:04AM CDT
While Bayer (BAYRY) has signed a merger agreement with Monsanto, Allergan will be acquiring Vitae.
AGN: 243.94 (+0.51), PFE: 34.26 (+0.11), AZN: 33.97 (-0.31), AERI: 39.07 (+1.02), TEVA: 51.47 (+0.24), SNY: 38.35 (-0.22)
Phase III Combination Trial of BYDUREON and FARXIGA Shows Significant Blood Sugar Reduction in Patients with Type 2 Diabetes
BusinessWire - Fri Sep 16, 7:30AM CDT
--The first Phase III trial to assess GLP-1RA/SGLT-2i combination therapy
AZN: 33.97 (-0.31)
SmarTrend Watching for Potential Pullback in Shares of AstraZeneca After 1.03% Gain
Comtex SmarTrend(R) - Thu Sep 15, 12:58PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $33.00 to a high of $33.49. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $33.34 on volume of 3.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AZN: 33.97 (-0.31)
Downgrade Alert for AstraZeneca (AZN)
Comtex SmarTrend(R) - Wed Sep 14, 3:29AM CDT
AstraZeneca (NYSE:AZN) was downgraded from Outperform to Neutral at Exane BNP Paribas today. The stock closed yesterday at $32.74 on volume of 5.7 million shares, above average daily volume of 3.7 million. In the past 52 weeks, shares of AstraZeneca have traded between a low of $26.97 and a high of $70.67 and closed yesterday at $32.74, which is 21% above that low price. Over the past week, the 200-day moving average (MA) has gone down 2.4% while the 50-day MA has declined 0.2%.
AZN: 33.97 (-0.31)
Biotech Stocks Bounce Back in Monday Trading: 3 Picks
Zacks Equity Research - Zacks Investment Research - Tue Sep 13, 8:12AM CDT
Media and political focus on the high prices of drugs have made things difficult for the pharma/biotech sector since the past one year.
ABT: 42.19 (-0.03), BIIB: 312.58 (-2.23), VNDA: 16.81 (+0.19), PFE: 34.26 (+0.11), AMGN: 174.80 (-0.82), AEGR: 2.75 (+0.10), LLY: 81.16 (-0.13), PDLI: 3.43 (+0.08), JNJ: 118.81 (-0.65), GILD: 81.37 (-0.15), AZN: 33.97 (-0.31), MRK: 62.96 (-0.06), SNY: 38.35 (-0.22), NVS: 81.48 (-0.55)
Upgrade Alert for AstraZeneca (AZN)
Comtex SmarTrend(R) - Tue Sep 13, 3:11AM CDT
AstraZeneca (NYSE:AZN) was upgraded from Hold to Buy at Jefferies today. The stock closed yesterday at $33.24 on volume of 3.6 million shares, below average daily volume of 3.7 million. Over the past year, AstraZeneca has traded in a range of $26.97 to $70.67 and closed yesterday at $33.24, 23% above that low. Over the past week, the 200-day moving average (MA) has gone down 2.4% while the 50-day MA has declined 0.2%.
AZN: 33.97 (-0.31)
Global Cancer Diagnostics Market - Development and Commercialization of Biomarkers for Cancer Diagnostics Opens up Growth Opportunities, Research Report by TMR
GlobeNewswire - Thu Sep 08, 5:44AM CDT
According to the research report, the global cancer diagnostic market is expected to be worth US$168.6 bn by 2020, as the market exhibits a CAGR of 7.6% between 2014 and 2020. Imaging has emerged as a significant segment as the government is making ardent efforts to increase awareness about cancer and cancer diagnostics to better the quality of life. Owing to this reason, imaging will be the most popularly used diagnostic method. The segment will progress at a CAGR of 9.7% between 2014 and 2020. Geographically, North America is anticipated to lead the global cancer diagnostics market at a CAGR of 7.3% between 2014 and 2020.
PFE: 34.26 (+0.11), AZN: 33.97 (-0.31), NVS: 81.48 (-0.55)
Astrazeneca (AZN) Presents Benralizumab Phase III Data
Zacks Equity Research - Zacks Investment Research - Tue Sep 06, 8:08AM CDT
AstraZeneca plc, (AZN) recently announced further results from two pivotal phase III trials on its respiratory disease candidate, benralizumab, for the treatment of severe asthma.
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), AZN: 33.97 (-0.31), ANIK: 46.92 (-1.07)
Benralizumab Phase III Trials Show Positive Results in Severe Asthma
BusinessWire - Mon Sep 05, 7:00AM CDT
Results from pivotal Phase III trials presented at the European Respiratory Society (ERS) International Congress demonstrated that adding benralizumab to standard-of-care medicine significantly reduced exacerbations and improved lung function and asthma symptoms in severe asthma patients with an eosinophilic phenotype, as indicated by the presence of eosinophils in their blood.
AZN: 33.97 (-0.31)
Biogen (BIIB) Aducanumab Gets Fast Track Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 8:33AM CDT
Biogen (BIIB) granted Fast Track designation in the U.S. for aducanumab for the treatment of early stage Alzheimer's disease.
BIIB: 312.58 (-2.23), AZN: 33.97 (-0.31), LLY: 81.16 (-0.13), ANIK: 46.92 (-1.07)
AstraZeneca Asthma Drug Symbicort Positive in Safety Trial
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:21AM CDT
AstraZeneca PLC (AZN) announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone.
BSTC: 45.26 (+1.22), AZN: 33.97 (-0.31), OHRP: 2.81 (+0.03)
AstraZeneca Announces SYMBICORT Demonstrated Comparable Risk of Serious Asthma-Related Events and Lower Risk of Asthma Exacerbations Compared to Budesonide Alone
BusinessWire - Wed Aug 31, 4:00PM CDT
AstraZeneca today announced results from the SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol LABA (long-acting beta2-adrenergic agonist) safety study showing patients with controlled and uncontrolled asthma had a comparable risk of serious asthma-related events and a lower risk of asthma exacerbations when formoterol was combined with budesonide versus budesonide alone.
AZN: 33.97 (-0.31)
SmarTrend Watching for Potential Rebound in Shares of AstraZeneca After 1.51% Loss
Comtex SmarTrend(R) - Wed Aug 31, 1:35PM CDT
AstraZeneca (NYSE:AZN) traded in a range yesterday that spanned from a low of $32.61 to a high of $32.84. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $32.78 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AZN: 33.97 (-0.31)
(0)
(0)Scroll down for more posts ▼